- Conditions
- Healthy Volunteers
- Interventions
- dMAb AZD5396, dMAb AZD8076, CELLECTRA™ 2000 with Side Port needle, OpBlock 0078 Electroporation device, Hylenex, CELLECTRA™ 2000 with Side Port needle, OpBlock 0070 Electroporation device
- Combination Product · Drug
- Lead sponsor
- Pablo Tebas
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 985–1008
of 17,144
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Recurrent Platinum Resistant Ovarian Cancer
- Interventions
- VB-111 + Paclitaxel, Placebo + Paclitaxel
- Drug
- Lead sponsor
- Vascular Biogenics Ltd. operating as VBL Therapeutics
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 408 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 64
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 56 more
- Conditions
- Lung Cancer
- Interventions
- Best Practice, Cancer Educational Materials, Behavioral, Psychological or Informational Intervention, Counseling
- Other · Behavioral
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 2,355 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- HIV
- Interventions
- Not listed
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- Not listed
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2010
- U.S. locations
- 7
- States / cities
- Washington D.C., District of Columbia • Fort Lauderdale, Florida • Miami, Florida + 4 more
- Conditions
- Compliance With Restrictive RBC Transfusion Guideline
- Interventions
- Feedback
- Behavioral
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- Not listed
- Enrollment
- 426 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Minneapolis, Minnesota • St Louis, Missouri + 2 more
- Conditions
- Pulmonary Embolism
- Interventions
- Hēlo PE Thombectomy System
- Device
- Lead sponsor
- Endovascular Engineering
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 21
- States / cities
- Los Angeles, California • Pasadena, California • Torrance, California + 13 more
- Conditions
- Tumor, Solid
- Interventions
- Indocyanine Green
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Solid Tumors
- Interventions
- nesvacumab (REGN910/ SAR307746), aflibercept (ziv-aflibercept)
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 5
- States / cities
- Indianapolis, Indiana • New York, New York • Oklahoma City, Oklahoma + 2 more
- Conditions
- Hypertension, Dyslipidemia
- Interventions
- Amlodipine/Atorvastatin
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2005
- U.S. locations
- 106
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 73 more
- Conditions
- Neuroblastoma
- Interventions
- MLN8237, Irinotecan, Temozolomide
- Drug
- Lead sponsor
- New Approaches to Neuroblastoma Therapy Consortium
- Other
- Eligibility
- 12 Months to 30 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more
- Conditions
- Secondary Hyperparathyroidism, Chronic Kidney Disease
- Interventions
- Etelcalcetide, Standard of Care
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 0 Years to 18 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Aurora, Colorado • Kansas City, Missouri + 7 more
- Conditions
- SARS-CoV-2, Covid-19
- Interventions
- Sirolimus 1 MG/ML, Placebo
- Drug
- Lead sponsor
- Walter K. Kraft
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Noise Exposure
- Interventions
- Not listed
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 401 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Endometrial Cancer
- Interventions
- filgrastim, cisplatin, doxorubicin hydrochloride, paclitaxel
- Biological · Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 59 more
- Conditions
- Idiopathic Short Stature
- Interventions
- Genotropin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 3 Years to 10 Years
- Enrollment
- 316 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 43
- States / cities
- Little Rock, Alaska • Little Rock, Arkansas • Los Angeles, California + 32 more
- Conditions
- Nephropathic Cystinosis
- Interventions
- DFT383
- Genetic
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 5 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2044
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • San Diego, California • Stanford, California + 3 more
- Conditions
- Knee Osteoarthritis
- Interventions
- SM04690, Placebo, Sham
- Drug · Other
- Lead sponsor
- Biosplice Therapeutics, Inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 74
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 68 more
- Conditions
- Obesity, Weight Gain, Diabetes Type 2
- Interventions
- Sugary drink warning labels
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,016 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Short Bowel Syndrome
- Interventions
- Placebo, Teduglutide 0.05 mg/kg/d, Teduglutide 0.1 mg/kg/d
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 14
- States / cities
- Scottsdale, Arizona • Washington D.C., District of Columbia • Atlanta, Georgia + 11 more
- Conditions
- Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- valproic acid
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 15
- States / cities
- Orange, California • Stanford, California • Washington D.C., District of Columbia + 12 more
- Conditions
- Sepsis, Severe Sepsis, Septic Shock
- Interventions
- Early Goal Directed Therapy (EGDT), Protocolized Standard Care (PSC), Usual Care (UC)
- Procedure
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,351 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 23 more
- Conditions
- Ulcerative Colitis and Crohn's Disease
- Interventions
- Vedolizumab, Other Biologic Agents
- Drug · Other
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 54 more
- Conditions
- Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
- Interventions
- Capecitabine, Carboplatin, Cisplatin
- Drug
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 415 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2031
- U.S. locations
- 1023
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 634 more
- Conditions
- Recurrent Osteosarcoma
- Interventions
- Glembatumumab Vedotin, Laboratory Biomarker Analysis, Pharmacological Study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years to 49 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 149
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 90 more